Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269059 | 0.90 | CA9 (0.43) | CA9MAPTKMT2ATDP1ALDH1A1 | |
| SCHEMBL4933068 | 0.88 | CA9 (0.42) | CA9MAPTKMT2ATP53JMJD6 | |
| SCHEMBL5265509 | 0.87 | ALDH1A1 (0.41) | KMT2AALDH1A1TSHR | |
| SCHEMBL5525755 | 0.86 | ALDH1A1 (0.37) | KMT2ATDP1ALDH1A1TSHRRAB9A | |
| SCHEMBL5525424 | 0.86 | TDP1 (0.38) | MAPTTDP1ALDH1A1TSHRFAAH | |
| SCHEMBL2912092 | 0.86 | CA9 (0.48) | CA9MAPTKMT2ATDP1ALDH1A1 | |
| SCHEMBL5529681 | 0.84 | MALT1 (0.38) | KMT2AALDH1A1TSHRRAB9A | |
| SCHEMBL4929151 | 0.84 | KMT2A (0.42) | CA9MAPTKMT2ATDP1ALDH1A1 | |
| SCHEMBL5528138 | 0.83 | ALDH1A1 (0.35) | ALDH1A1TSHRRAB9A | |
| SCHEMBL4932988 | 0.81 | ALDH1A1 (0.53) | CA9MAPTKMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3231/4885MAPT 4006/4885KMT2A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.